Exhibit 10.6
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
EXECUTION VERSION
CONFIDENTIAL
July [●], 2026
** **
VIA ELECTRONIC MAIL
CONFIDENTIAL
Mirador Therapeutics, Inc.
4902 Headquarters Point, Suite 300
San Diego, CA 92121
Attention: Chief Legal Officer, Timothy K. Andrews
Email: [***]
Re: Payment of Certain Costs and Cover of Licensed Antibody
** **
Ladies and Gentlemen:
This letter agreement (“Letter Agreement”) is entered into by and between Kira Pharmaceuticals, a corporation registered and existing under the laws of the Cayman Islands (“Kira”) and Mirador Therapeutics, Inc., a corporation organized under the laws of The State of Delaware (“Mirador”). Kira and Mirador may be collectively referred to herein as the “Parties”. Reference is made to (a) that certain Term Sheet for Exclusive License Agreement with Kira Pharma, dated June 9, 2026 (the “Term Sheet”), by and between Kira and Mirador; (b) that certain License Agreement, dated July 13, 2026 (the “Mirador-Kira License”), by and among Mirador, Kira and, solely with respect to Section 10.22 therein, Kira Pharmaceuticals (Suzhou) Ltd.; and (c) that certain License Agreement, dated June 9, 2017 (the “Penn License”), by and between Kira and the Trustees of the University of Pennsylvania (“Penn”), as amended on June 7, 2019, February 4, 2021, and July 9, 2026.
The Parties hereby acknowledge and agree as follows:
(a) Pursuant to the “Testing of Physical Materials Conducted by 3rd Parties” section of the Term Sheet, Mirador agreed to pay or reimburse Kira (as applicable) for all costs associated with (i) the testing of physical materials conducted by a third party as agreed upon by the Parties in writing, including testing under Quote No. [***] by HTL Biosolutions, Inc., and (ii) any additional work orders contracted for at the request of Mirador prior to execution of the Mirador-Kira License (such costs collectively, the “Testing Costs”). Within fifteen (15) days following Kira’s written request, Mirador shall, at Kira’s direction, either (y) pay all applicable undisputed Testing Costs directly to the third party that performed the relevant testing services, or (z) reimburse Kira for such undisputed Testing Costs paid by Kira to such third party by making payment by wire transfer or Automated Clearing House (ACH) payment to an account designated by Kira. Any payment made to Kira pursuant to the preceding sentence shall be made separate from any payment to be made by Mirador to Kira pursuant to the Mirador-Kira License or any strategic investment in Kira to be made by Mirador. Exhibit A, attached hereto, sets forth certain Testing Costs incurred by Kira as of the date of this Letter Agreement.
(b) The Licensed Antibody (as defined in the Mirador-Kira License) is Covered (as defined in the Mirador-Kira License) by the “[***] Patent Family” under Section 3.3.1 of the Penn License.
The Parties hereby execute and deliver this Letter Agreement as of the date of last signature set forth below. This Letter Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.
[Signature page to follow.]
Please indicate your acceptance by signing this Letter Agreement and returning an executed copy to Kira.
| Sincerely, | ||
| KIRA PHARMACEUTICALS | ||
| By: | /s/ Patrick Crutcher | |
| Name: | Patrick Crutcher | |
| Title: | Director | |
| Date: | July 12, 2206 |
| ACKNOWLEDGED AND AGREED: | ||
| MIRADOR THERAPEUTICS, INC. | ||
| By: | /s/ Mark C. McKenna | |
| Name: | Mark C. Mckenna | |
| Title: | Chairman and Chief Executive | |
| Date: | July 13, 2026 |
Exhibit A
** **
Costs
[***]